120 related articles for article (PubMed ID: 1795436)
1. [Separation of high density lipoprotein (HDL) using anti-apo A-I, apo A-II immuno-affinity chromatography to evaluate the effects of probucol].
Kagami A; Hino K; Mochizuki K; Sakamoto T; Tada N; Ishikawa T; Manabe M; Satoh N
Nihon Ronen Igakkai Zasshi; 1991 Nov; 28(6):748-54. PubMed ID: 1795436
[TBL] [Abstract][Full Text] [Related]
2. Effects of probucol and pravastatin on plasma lipids, activities of postheparin lipoprotein lipase, and lecithin cholesterol acyltransferase and apo A-I containing lipoproteins with and without apo A-II in patients with moderate hypercholesterolemia.
Kagami A; Ishikawa T; Tada N; Sakamoto T; Mochizuki K; Nagano M; Moriguchi EH; Manabe M
Clin Biochem; 1993 Apr; 26(2):101-7. PubMed ID: 8485855
[TBL] [Abstract][Full Text] [Related]
3. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
[TBL] [Abstract][Full Text] [Related]
4. Probucol promotes reverse cholesterol transport in heterozygous familial hypercholesterolemia. Effects on apolipoprotein AI-containing lipoprotein particles.
Adlouni A; El Messal M; Saïle R; Parra H; Fruchart J; Ghalim N
Atherosclerosis; 2000 Oct; 152(2):433-40. PubMed ID: 10998472
[TBL] [Abstract][Full Text] [Related]
5. Combined therapy with probucol and pravastatin in hypercholesterolaemia. One year follow-up study.
Saku K; Zhang B; Hirata K; Okura Y; Bai H; Liu R; Arakawa K
Eur J Clin Pharmacol; 1993; 44(6):535-9. PubMed ID: 8405008
[TBL] [Abstract][Full Text] [Related]
6. Probucol treatment in hypercholesterolemic patients: effects on lipoprotein composition, HDL particle size, and cholesteryl ester transfer.
Bagdade JD; Kaufman D; Ritter MC; Subbaiah PV
Atherosclerosis; 1990 Oct; 84(2-3):145-54. PubMed ID: 2282096
[TBL] [Abstract][Full Text] [Related]
7. Characterization of apolipoprotein A-I- and A-II-containing lipoproteins in a new case of high density lipoprotein deficiency resembling Tangier disease and their effects on intracellular cholesterol efflux.
Cheung MC; Mendez AJ; Wolf AC; Knopp RH
J Clin Invest; 1993 Feb; 91(2):522-9. PubMed ID: 8432861
[TBL] [Abstract][Full Text] [Related]
8. High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate.
Saku K; Zhang B; Jimi S; Bai H; Hirata K; Sasaki N; Liu R; Arakawa K
Eur J Clin Pharmacol; 1995; 48(3-4):209-15. PubMed ID: 7589043
[TBL] [Abstract][Full Text] [Related]
9. Interaction between high-density lipoprotein subpopulations in apo B-free and abetalipoproteinemic plasma.
Cheung MC; Wolf AC; Illingworth DR
Biochim Biophys Acta; 1992 Oct; 1128(2-3):244-9. PubMed ID: 1420297
[TBL] [Abstract][Full Text] [Related]
10. Effects of gonadotropin and testosterone treatments on Lipoprotein(a), high density lipoprotein particles, and other lipoprotein levels in male hypogonadism.
Ozata M; Yildirimkaya M; Bulur M; Yilmaz K; Bolu E; Corakci A; Gundogan MA
J Clin Endocrinol Metab; 1996 Sep; 81(9):3372-8. PubMed ID: 8784099
[TBL] [Abstract][Full Text] [Related]
11. Characterization of monoclonal antibodies against apolipoproteins A-I and A-II. Epitope expression in LpA-I and LpA-I:A-II particles.
Ulloa N; Bustos P; Castro G; Fruchart J; Vera M; Fruchart JC; Calvo C
Hybridoma; 1999 Dec; 18(6):513-20. PubMed ID: 10626680
[TBL] [Abstract][Full Text] [Related]
12. Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
Matsuzawa Y; Yamashita S; Funahashi T; Yamamoto A; Tarui S
Am J Cardiol; 1988 Jul; 62(3):66B-72B. PubMed ID: 3394656
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of triphasic oral contraceptives with desogestrel or levonorgestrel on apolipoprotein A-I-containing high-density lipoprotein particles.
Cheung MC; Walden CE; Knopp RH
Metabolism; 1999 May; 48(5):658-64. PubMed ID: 10337871
[TBL] [Abstract][Full Text] [Related]
14. Effect of probucol treatment on lipoprotein cholesterol and drug levels in blood and lipoproteins in familial hypercholesterolemia.
Fellin R; Gasparotto A; Valerio G; Baiocchi MR; Padrini R; Lamon S; Vitale E; Baggio G; Crepaldi G
Atherosclerosis; 1986 Jan; 59(1):47-56. PubMed ID: 3081013
[TBL] [Abstract][Full Text] [Related]
15. Selective uptake of cholesteryl esters from high-density lipoprotein-derived LpA-I and LpA-I:A-II particles by hepatic cells in culture.
Rinninger F; Kaiser T; Windler E; Greten H; Fruchart JC; Castro G
Biochim Biophys Acta; 1998 Aug; 1393(2-3):277-91. PubMed ID: 9748629
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein A-I-containing lipoproteins, with or without apolipoprotein A-II, as progenitors of pre-beta high-density lipoprotein particles.
Hennessy LK; Kunitake ST; Kane JP
Biochemistry; 1993 Jun; 32(22):5759-65. PubMed ID: 8504094
[TBL] [Abstract][Full Text] [Related]
17. Effects of a diet restricted in saturated fatty acids and cholesterol on the composition of apolipoprotein A-I--containing lipoprotein particles in the fasting and fed states.
Cheung MC; Lichtenstein AH; Schaefer EJ
Am J Clin Nutr; 1994 Dec; 60(6):911-8. PubMed ID: 7985633
[TBL] [Abstract][Full Text] [Related]
18. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
[TBL] [Abstract][Full Text] [Related]
19. High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics.
Ji J; Watts GF; Johnson AG; Chan DC; Ooi EM; Rye KA; Serone AP; Barrett PH
J Clin Endocrinol Metab; 2006 Mar; 91(3):973-9. PubMed ID: 16368749
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance.
Fruchart JC; Ailhaud G
Clin Chem; 1992 Jun; 38(6):793-7. PubMed ID: 1597003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
